The Pharmaceutical And Biotech Companies Working to Develop Gene Therapies Treatments For Dermatology

ByKevin

Previously, the only application of gene therapy was treating symptoms rather than confronting the root of the disease in dermatology. But progress in genetics research has increased the scope of gene therapy treatment beyond topical drugs. It now incorporates treatment methods like light and laser therapy, injectables, and oral medications. However, many challenges are yet to be overcome, since the subject of gene therapy in dermatology is still a relatively new concept.


The finite availability of patient populations for conducting trials is another considerable challenge, due to which gene therapy in dermatology is always on an accelerated development pathway. Nevertheless, major pharmaceutical companies are inspecting the subject of gene therapy in dermatology with all their expertise and are striving to bring novel drugs to the market. The following list gives a brief detail of some of these pharmaceutical companies, along with their lead products.

Key Companies In Gene Therapy For Dermatology

  • Krystal Biotech, Inc.

  • Castle Creek Biosciences, Inc.

  • Abeona Therapeutics

  • Amryt Pharma

  • Holostem Terapie

  • Avita Medical

  • Azitra

Emerging therapies In Gene Therapy For Dermatology

  • Beremagene geperpavec (Krystal Biotech, Inc.)  for treatment of dystrophic epidermolysis bullosa.

  • D-Fi (dabocemagene autoficel, formerly known as FCX-007) (Castle Creek Biosciences, Inc.)  for the treatment of autosomally recessive or dominant dystrophic epidermolysis bullosa.

  • FCX-013 (Castle Creek Biosciences, Inc.) for the treatment of moderate to severe localized scleroderma.

  • EB-101 (Abeona Therapeutics) for the treatment of recessive dystrophic epidermolysis bullosa.

  • AP103 (Amryt Pharma) for the treatment of dystrophic epidermolysis bullosa.

  • Laminin 332-JEB (Holostem Terapie) for the treatment of recessive dystrophic epidermolysis bullosa.

  • RECELL System technology (Avita Medical) for the treatment of genodermatoses and skin rejuvenation.

  • ATR-12 (Azitra) for the treatment of Netherton syndrome (NS).

Click here to know more about the Key Companies and the Emerging Gene Therapy in the Dermatology Segment

Conclusion

Apart from the above-mentioned companies, there are many more key companies in gene therapy for the dermatology segment, working continuously to satisfy the unmet demands of treatment options for rare conditions in skin diseases. These include Almirall, Tyris Therapeutics, Sterna Biologicals, Fibrocell Science, Temprian Therapeutics, Novartis, and others.